🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525434-33-00
Authorised Phase I

Bioequivalence Study of Empagliflozin

2026-525434-33-00 · tracked via the Priya Life Science EU tracker
Sponsor
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Sponsor type
Pharmaceutical company
Therapeutic area
Nutritional and Metabolic Diseases
Decision date
11/03/2026
Enrollment target
32
Sites
Czechia

Condition studied

Not applicable (submitted trial is a BE study in healthy participants)

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525434-33-00 on CTIS ↗ ← All trials in the EU